Aplagon Oy is a private pharmaceutical development company committed to addressing major unmet clinical needs and bringing unique, effective vasculoprotective, antithrombotic medicines with important efficacy and safety advantages to cardiovascular disease patients.
THE UNMET NEED
Cardiovascular diseases carry significant morbidity and mortality. They are in general driven by overactive coagulation at the sites of vascular injury, caused by disease processes, such as atherosclerosis and vascular inflammation. The currently available therapies only partially address these clinical problems.
Aplagon is based on pioneering research on mast cell-derived heparin proteoglycans (HEP-PG) performed by Prof. Riitta Lassila’s group at Wihuri Research Institute in Helsinki, Finland. These early discoveries led to Aplagon’s product, APAC, a heparin proteoglycan mimetic. After years of building a robust body of scientific evidence, the Company’s lead APAC is now in clinical studies with the goal of demonstrating preliminary efficacy and safety in 2-3 indications.
Aplagon has its offices and laboratory at Biomedicum Helsinki, the most prominent life science hub in Finland. Aplagon also works with a wide network of international collaboration partners.
Aplagon has a strong IP protection for APACs.
Aplagon is backed by a syndicate of leading Finnish investors.